A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
A 52-Week Multicenter, Open-Label, Randomized, Parallel, Two - Arm Study Comparing Exubera® (Inhaled Human Insulin) Vs. Humalog® (Insulin Lispro), Both In Combination With Insulin Glargine In Subjects With Type 1 Diabetes Mellitus
Sponsor: Pfizer
Terminated
See termination reason in detailed description.
Other terminated trials from Pfizer
Other Diabetes Mellitus, Type 1 trials with similar outcome
This PHASE4 trial investigates Diabetes Mellitus, Type 1 and is currently terminated or withdrawn. Pfizer leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
▶ Show 4 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Sep 2020 [monthly]
Terminated PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .